MeSH tree: D12.776.377.715.548.114.224.200.875
Researchers at the University of Oulu have made a discovery in breast cancer research. They demonstrated that the extracellular matrix protein collagen XVIII significantly promotes breast cancer progression and metastasis. ...
Oct 17, 2023
0
49
Research and development (R&D) costs for targeted oncology drugs are markedly lower if guided by a companion diagnostic strategy, but current biopharmaceutical business models suggest these savings will not be reflected in ...
Aug 21, 2023
0
56
Breast cancer survival rates have improved considerably in the last few decades in Colombia, but factors that increase the likelihood of patients experiencing cardiovascular side effects, like cardiotoxicity, are not well-known ...
Aug 2, 2023
1
39
The U.S. biosimilar drug market emerged in 2015 to provide safe, effective, and more affordable alternatives to existing biologic drugs, but it has been slow to develop compared with Europe.
Jun 6, 2023
0
50
Gastric cancer is the fifth most commonly diagnosed malignancy worldwide. It ranks a sad third in cancer-related causes of death. The reason for this is late diagnosis coupled with rapid spread of tumor cells in the body.
May 8, 2023
0
59
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells ...
Jan 5, 2023
0
61
First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), ...
Dec 20, 2022
0
31
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated ...
Dec 7, 2022
0
31
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated ...
Dec 7, 2022
0
23
The microenvironment surrounding tumors in HER2+ breast cancer protects them and helps them develop resistance to the most widely used treatment, the monoclonal antibody trastuzumab. And a particular type of cell in this ...
Oct 14, 2022
0
80
